Sevelamer in a diabetologist's perspective: A phosphate-binding resin with glucose-lowering potential
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Sevelamer in a diabetologist's perspective : A phosphate-binding resin with glucose-lowering potential. / Brønden, A.; Hansen, M.; Sonne, D. P.; Rohde, U.; Vilsbøll, T.; Knop, Filip K.
I: Diabetes, Obesity and Metabolism, Bind 17, Nr. 2, 01.02.2015, s. 116-120.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Sevelamer in a diabetologist's perspective
T2 - A phosphate-binding resin with glucose-lowering potential
AU - Brønden, A.
AU - Hansen, M.
AU - Sonne, D. P.
AU - Rohde, U.
AU - Vilsbøll, T.
AU - Knop, Filip K.
N1 - Publisher Copyright: © 2014 John Wiley & Sons Ltd.
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Sevelamer is a calcium-free and metal-free phosphate-binding oral drug used in the management of hyperphosphataemia in chronic kidney disease. Preclinical and clinical trials have shown glucose and lipid-lowering effects of sevelamer, thereby giving rise to a potential role of the drug in the treatment of patients with type 2 diabetes. These 'novel' effects are most probably derived from the bile acid-binding properties of sevelamer. The proposed potential is supported by the approval of the bile acid sequestrant colesevelam in the United States for the treatment of type 2 diabetes and hypercholesterolaemia. This article offers a brief review on the effects of sevelamer and a perspective on the potential mechanisms behind the glucose-lowering effect of the drug.
AB - Sevelamer is a calcium-free and metal-free phosphate-binding oral drug used in the management of hyperphosphataemia in chronic kidney disease. Preclinical and clinical trials have shown glucose and lipid-lowering effects of sevelamer, thereby giving rise to a potential role of the drug in the treatment of patients with type 2 diabetes. These 'novel' effects are most probably derived from the bile acid-binding properties of sevelamer. The proposed potential is supported by the approval of the bile acid sequestrant colesevelam in the United States for the treatment of type 2 diabetes and hypercholesterolaemia. This article offers a brief review on the effects of sevelamer and a perspective on the potential mechanisms behind the glucose-lowering effect of the drug.
KW - Bile acid sequestrant
KW - Chronic kidney disease
KW - Diabetes
KW - HbA1c
KW - Phosphate resin
UR - http://www.scopus.com/inward/record.url?scp=84921436822&partnerID=8YFLogxK
U2 - 10.1111/dom.12355
DO - 10.1111/dom.12355
M3 - Review
C2 - 25041567
AN - SCOPUS:84921436822
VL - 17
SP - 116
EP - 120
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
SN - 1462-8902
IS - 2
ER -
ID: 305736654